B I O P E O P L E
Immuneel Therapeutics named Amit Mookim as CEO
Immuneel Therapeutics has named Amit Mookim as its new CEO . Mookim , with over 20 years in life sciences and private equity , joins from IQVIA , where he was Managing Director for South Asia . At Immuneel , he will focus on expanding access to innovative immunotherapies across India .
Previously , Mookim led KPMG India ’ s healthcare division , advised on public health initiatives , and contributed to major industry organizations .
Dr . Kiran Mazumdar-Shaw , Cofounder of Immuneel , praised Mookim ’ s strategic vision and healthcare expertise . Mookim will oversee expanding Immuneel ’ s footprint , forging partnerships , and scaling operations to deliver transformative therapies both in India and globally .
Enzene Biosciences appoints Norm Stoffregen as SVP for new $ 50 million biologics facility
Enzene Biosciences has appointed Norm Stoffregen as Senior Vice President , site head , and head of biologics manufacturing at its new $ 50 million continuous manufacturing facility in Hopewell , New Jersey . Stoffregen will oversee the final commissioning and operations of the 54,000-square-foot site , which will play a crucial role in Enzene ’ s U . S . expansion and its goal of reducing biologics production costs .
The Hopewell facility , near Princeton , will be integral to Enzene ’ s global network and will feature the EnzeneX™ continuous manufacturing platform , along with advanced laboratories and storage solutions . Stoffregen , with over 20 years in biomanufacturing , will also manage Enzene ’ s global biologics business and drive the site ' s growth , aiming to employ 300 staff and increase bioreactor capacity by late 2025 .
73
BioVoiceNews | October 2024